Association between double mutation in gyrA gene of ciprofloxacin- resistant clinical isolates of Escherichia coli and MICs
- J. Vila,
- ,
- F. Marco,
- A. Barcelo,
- P. Goni,
- E. Giralt
- Hospital Clinic Barcelona,
Open access
Publication Information
Output type
Original language
EnglishPages from-to (Number of pages)
Pages 2477-2479 (3 pages)Journal (Volume, Issue Number)
Antimicrobial Agents and Chemotherapy (Volume 38, Issue 10)Publication milestones
- Published - 1994
Publication status
ISSN
0066-4804Publication IDs
- Scopus: 0028144813
- PubMed: 7840592
Abstract
The mutations in the quinolone resistance-determining region of the gyrA and gyrB genes from 27 clinical isolates of Escherichia coli with a range of MICs of ciprofloxacin from 0.007 to 128 μg/ml and of nalidixic acid from 2 to >2,000 μg/ml were determined by DNA sequencing. All 15 isolates with ciprofloxacin MICs of ≥1 μg/ml showed a change in Ser-83 to Leu of GyrA protein, whereas in clinical isolates with a MIC of ≥8 μg/ml (11 strains), a double change in Ser-83 and Asp-87 was found. All isolates with a MIC of nalidixic acid of ≥128 μg/ml showed a mutation at amino acid codon Ser-83. Only 1 of the 27 clinical isolates of E. coli analyzed showed a change in Lys-447 of the B subunit of DNA gyrase. A change in Ser-83 is sufficient to generate a high level of resistance to nalidixic acid, whereas a second mutation at Asp-87 in the A subunit of DNA gyrase may play a complementary role in developing the strain's high levels of ciprofloxacin resistance.
Access to documents
Publication metrics
Metrics
PlumX, opens in new tab
Sustainable Development Goals
- SDG 3 Good Health and Well
